Weekly XOMA Corporation (NASDAQ:XOMA) Ratings as of May 17, 2018

May 17, 2018 - By Matthew Richard

XOMA Corporation (NASDAQ:XOMA) Corporate Logo

XOMA Corporation (NASDAQ:XOMA) Ratings Coverage

In total 2 analysts cover Xoma Corp (NASDAQ:XOMA). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:XOMA) has 100% bullish analysts. 6 are the (NASDAQ:XOMA)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. The stock rating was maintained by H.C. Wainwright with “Buy” on Thursday, December 7. On Tuesday, February 6 Wedbush maintained XOMA Corporation (NASDAQ:XOMA) rating. Wedbush has “Buy” rating and $33.0 target. In Tuesday, December 19 report Wedbush maintained the stock with “Buy” rating. In Monday, April 30 report H.C. Wainwright maintained the stock with “Buy” rating. On Friday, March 9 the company was maintained by H.C. Wainwright. On Thursday, January 18 the firm has “Buy” rating by H.C. Wainwright given. Listed here are XOMA Corporation (NASDAQ:XOMA) PTs and latest ratings.

30/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $49.0000 Maintain
09/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $49.0 Maintain
06/02/2018 Broker: Wedbush Rating: Buy New Target: $33.0 Maintain
18/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $49.0 Maintain
19/12/2017 Broker: Wedbush Rating: Buy New Target: $33.0 Maintain
07/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $38.0 Maintain

XOMA touched $24.6 during the last trading session after $0.68 change.Currently XOMA Corporation is uptrending after 184.45% change in last May 17, 2017. XOMA has also 72,030 shares volume. The stock outperformed the S&P 500 by 172.90%.

XOMA Corporation discovers, develops, and commercializes antibody therapeutics in the United States, Europe, and the Asia Pacific.The firm is valued at $205.83 million. The companyÂ’s product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia.The P/E ratio is 11.2. The Company’s preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy.

Another two news for XOMA Corporation (NASDAQ:XOMA) were recently released by: Globenewswire.com on May 02, 2018 with title “New Research: Key Drivers of Growth for HTG Molecular Diagnostics, Impinj, XOMA, Stock Yards, TriCo Bancshares …”. The other Nasdaq.com‘s article was titled “XOMA Reports First Quarter 2018 Financial Results” and released on May 09, 2018.

XOMA Corporation (NASDAQ:XOMA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.